¹Ð?¨¾ªv¡Ð°¨°º¸gÅç

¥x¥_°¨°º¬ö©ÀÂå°|¤p¨à¹L±Ó§K¬Ì¬ì °¨¯q¸sÂå®v
¥x¥_°¨°º¬ö©ÀÂå°|¤p¨à¹L±Ó§K¬Ì¬ì ®}¥@¹F¥D¥ô
  ¡@¡@ªñ¦~¨Ó¡AÂå¾Ç¬É¤w¸gÁA¸Ñ¿ò¶Ç©Ê¹L±Ó¯f°ò¥»¤W¤D¬O¤@ºØ»P¦h­«°ò¦]¿ò¶Ç¦³ÃöªººC©Ê¹L±Ó©Êµoª¢¤ÏÀ³¡C¦¹ª¢¯g¤ÏÀ³·|¦]¨ü¨ì¦UºØ»¤µo¦]¯Àªº¿Eµo³y¦¨Á{§É¤Wªº¹L±Óµo§@¡A¦Ó¨äµo§@ªº³¡¦ì«h»P¨ä©Ò¿ò¶Ç¨ìªº¦U§O¾¹©x²§±`¦³±K¤ÁªºÃö«Y¡C·í¦¹ª¢¯g¤ÏÀ³µo¥Í©ó¤ä®ðºÞ®É¡A§Ú­ÌºÙ¤§¬°®ð³Ý¯f¡Fµo¥Í©ó»óµÄ¡B²´µ²½¤®É¡AºÙ¤§¬°¹L±Ó©Ê»óª¢¡B¹L±Ó©Êµ²½¤ª¢¡Fµo¥Í©ó­G¸z¹D®É¡AºÙ¤§¬°¹L±Ó©Ê­G¸zª¢¡F¦Ó·í¨äµo¥Í©ó¥Ö½§®É¡A§Ú­ÌºÙ¤§¬°²§¦ì©Ê¥Ö½§ª¢¡C

¡@¡@¦b©Ò¦³¿ò¶Ç©Ê¹L±Ó¯f·í¤¤¡A¥H´¿³y¦¨¦h¦ìª¾¦W¤H¤h¦º¤`¤Î¨äµo§@®É¦³Àb¤HÁ{§ÉÄY­««×ªº®ð³Ý¯f¡A³Ì¨ü¤H­«µø¡C®ð³Ý¯fªø¤[¥H¨Ó§Y¬°¦U°ê©Ò­«µøªº°ê¥Á°·±d°ÝÃD¡A¬°¤H­ÌµLªk¤u§@©Î´N¾Ç¨àµ£¯Ê½Òªº±`¨£­ì¦]¡C¨ä¿©¯f²v»P¦º¤`²v¦b¥þ²y¤j¦h¼Æªº¦a°Ï¥ç¦³³v¦~¼W¥[ªº¶É¦V¡A¥x¤jÂå°|¤p¨à¬ì¬GÁ¶Q¶¯±Ð±Â´¿¦b¥L©Ò¥D¾É½Õ¬dªº¤j¥x¥_¦a°Ï¾Çµ£®ð³Ý¯f¿©¯f²v³ø§i¤¤µo²{¡A®ð³Ý¿©¯f²v¤w¥Ñ¥Á°ê63¦~ªº¦Ê¤À¤§¤@ÂI¤T¡A¼W¥[¦Ü¥Á°ê73¦~ªº¦Ê¤À¤§¤QÂI¤C¤E¡AÅã¥Ü¦³©úÅã¼W¥[ªº²{¶H¡Cªñ¦~¨Ó¡A¥t¥~¨â¦¸ªº¤j¥x¥_¦a°Ï¾Çµ£®ð³Ý¯f¿©¯f²vªº°Ý¨÷½Õ¬d(¥Á°ê87»P91¦~) ¡A¨äµ²ªG§ó¬O§Ö³t¼W¥[¨ì¦Ê¤À¤§¤Q¤»»P¦Ê¤À¤Q¤E¡C¦Ó®ð³Ý¯fªº¦º¤`²v¡A¦b¥Á°ê91¦~¥H«e¤@ª½³£¬O¥xÆW¦a°Ï¨C¦~¤Q¤j¦º¤`­ì¦]¤§¤@¡A¨ì¤F¥Á°ê91¦~¤~­°¬°²Ä¤Q¤@¦ì¡C¥Ø«e¨C¦~¤´¬ù¦³¤@¤d¤»¦Ê¦ì®ð³Ý¯f¤H¦]®ð³Ýµo§@¦Ó¦º¤`¡C

¡@¡@³q±`§Ú­Ì¥i±N»¤µo¹L±Ó©ÊÅé½èµo§@ªº¦]¯À¤À¬°¨â¤jÃþ¡A²Ä¤@Ãþ¦]¯À¬°©I§l¹D¯f¬r·P¬V¡B¹L±Ó­ì(¤×¨ä¬O©~®aÀô¹Ò¤¤ªº¹Ð?»P¿ßª¯µ¥¦³¤òÃdª«)¡B©M¤Æ¾Ç¨ë¿Eª«(¤×¨ä¬O­»·Ï©Ò§tªº¥§¥j¤B) ¡A¥iª½±µ»¤µo¹L±Ó©ÊÅé½èµo§@¡F¦Ó²Ä¤GÃþ¦]¯À¦p«ùÄò¼@¯P¹B°Ê¡B­¹¥Î¦B§N­¹«~¡B¤Ñ®ðÀã«×·Å«×ªº¿E¯PÅܤÆ(¨Ò¦p©u¸`¶i¤J°®§Nªº¬î¤Ñ©Î¬O¤È«á¹p°}«B)¡B¶i¥X§N®ð©Ð¨ä«Ç¤º¥~·Å®t¤j©óÄá¤ó7oC¡B©Mºë¯«±¡ºüªº¤£Ã­©w(¦pª±±o¤Ó¿³¾Ä©Î¬O®Á½|¤ß±¡«ÜÆ{´e)µ¥¡A«h¥u·|¹ï¦­¤w¦s¦b¹L±Ó©Êµoª¢¥B¤w°ª¹L±Ó«×ªº¼Ð¦a¾¹©x¦p¤ä®ðºÞµ¥¡A³y¦¨¨ä¼È®É©Êªº¦¬ÁY¤ÏÀ³¡C¥u­n¯f¤HªººC©Ê¹L±Ó©Êµoª¢¤ÏÀ³¸g¹L¹L±Ó§K¬Ì¾Ç±M¬ìÂå®vªº¾A·í³B¸mÀò±o§ïµ½«á¡A¯f¤H§Y¥i¤£¦A¨ü¨ä¼vÅT¡F¤]´N¬O»¡¡A¹L±Ó¯f¤Hí©w¥H«á¡A§Y¨Ï°Ñ¥[¶ø¹B·|°¨©ÔªQÁɶ]©Î¬O­¹¥Î¦B²N²O³£¤£·|¦A»¤µo¹L±Óµo§@¡C

¡@¡@¦b¥xÆW¡A¤Þ°_¨àµ£¹L±Ó¯f±`¨£ªº§l¤J©Ê¹L±Ó­ì¦³®a¹Ð¡B¹Ð?¡Bª¯¥Ö®h¡BÁ­½¸¡B¿ß¥Ö®h¡BÅðµß¡B¦Ð¤ò¡B©Mªá¯»µ¥¡C±`¨£ªº­¹ª«©Ê¹L±Ó­ì«h¥]¬A¤û¥¤¡B³J¥Õ¡B÷«³½¡B°F´ß®üÂA¡B½¼¤l¡B©M¿ÀÃɵ¥¡C¦b¤j³¡¤À·Å·x¼éÀ㪺¦a°Ï¡A®a¹Ð?¬O®a¤¤³Ì¥D­nªº¹L±Ó­ì¡C¥¦·|¾É­P¦hºØ¹L±Ó©Ê¯e¯f¡A¨Ò¦p¹L±Ó©Ê»óª¢¡B®ð³Ý¤Î²§¦ì©Ê¥Ö½§ª¢µ¥¡C®Ú¾Ú§Ú­Ìªº¸gÅç¡A¦b¥xÆW»¤µo¤p¨à¹L±ÓÅé½èµo§@ªº³Ì­«­n¹L±Ó­ì¤´¥H¹Ð?³Ì¦h¡A¬ù¦û¦Ê¤À¤§¤E¤Q¥H¤W¡CÀô«O¸p´¿©e°U¥xÆW¤j¾Ç©øÂΨt®}º¸¯P±Ð±Â¶i¦æ?¬Û½Õ¬d¡Aµ²ªGµo²{¥xÆW¦a°Ï¦Ê¤À¤§¤C¤Q¤­ªº¦í®a¤¤¥R¥¸µÛ¹Ð?¡A«Ç¤º¨C¤½§J¦Ç¹Ð¤¤ÁôÂõۥ­§¡¨â¤d°¦¬Æ¦Ü¦³ªº°ª¹F¤@¸U°¦¥H¤Wªº¹Ð?¡A»·°ª©ó»¤µo¹L±Ó®ð³Ý©Ò»Ý­nªº¨C¤½§J¦Ç¹Ð¤@¦Ê¦Ü¤@¤d°¦¥H¤W¹Ð?ªº¿@«×¡C¦Ó¥xÆW¦a°Ï©~®a«Ç¤ºÁ`?¼Æ¤À¥¬¥H¦a´à³Ì¦h¡A¨ä¦¸¬°´Ö³Q¡B§É¹Ô¡BªEÀY¡B¦aªO¡B¤Î¨Fµo¡C¦Ó¦b¥xÆW¦a°Ïªº¤£¦P©~®a¹Ð?ºØÃþ¤¤¡A¥H«Î¹Ð?¡]Dermatophagoides pteronyssinus¡FDP¡^ªº¼Æ¶q³Ì¦h¡A¬ù¥e55%¨ì75%¡A¯»¹Ð?¡]Dermatophagoides farinae¡FDF¡^¦¸¤§¡A¦Ó³o¨âºØ¹Ð?³q±`·|¤Þ°_®ð³Ý¡B¹L±Ó©Ê»óª¢¡B¹L±Ó©Êµ²½¤ª¢¡BëC³Â¯l»P²§¦ì©Ê¥Ö½§ª¢¡C®Ú¾Ú¥x¥_°¨°º¬ö©ÀÂå°|°w¹ï3687¦ì®ð³Ý¯fµ£©Ò¶i¦æªº¥xÆW¦a°Ï¤KºØ±`¨£¹L±Ó­ì(«Î¹Ð?¡B¯»¹Ð?¡Bª¯¥Ö®h¡B¿ß¥Ö®h¡B¼w°êÁ­½¸¡B³J¥Õ¡B¤û¥¤¡B©M÷«³½) ªº¯S²§©ÊIgE§ÜÅé¬ã¨sÅã¥Ü¡A¦b¤Q¤G·³¥H«e¡A¨k©Ê®ð³Ý¯fµ£¤ñ¤k©Ê®ð³Ý¯fµ£¬°¦h¡A¦ý¬O¤j©ó¤Q¤G·³¥H¤W¡A«h¤k©Ê®ð³Ý¯fµ£¤ñ¨k©Ê®ð³Ý¯fµ£¬°¦h¡A¥B¦b¥xÆW¦a°Ï®ð³Ý¯f¨à¹ï³o¨âºØ¹Ð?¹L±Ó¯S²§©ÊIgE§ÜÅ鶧©Ê²vÀH¯fµ£¦~ÄÖªº¼W¥[¦Ó¼W¥[¡A¥Ñ¨â·³¯fµ£ªºDP35.80%¡ADF32.84%¡F¤T·³¯fµ£ªºDP44.72%¡ADF42.41%¡F¤»·³¯fµ£ªºDP63.02%¡ADF58.60%¡F¼W¥[¨ì¤Q¤G·³¥H¤W¯fµ£ªºDP81.36%¡ADF79.66%¡C©Ò¥H¤F¸Ñ¹Ð?ªº¥ÍºA¶i¦Ó­°§C®a¤¤¹Ð?¹L±Ó­ìªº¿@«×¬O¨è¤£®e½wªº¨Æ¡C

¡@¡@ÁקK¹L±Ó­ì¡A§ïµ½©~®aÀô¹Ò(¤×¨ä¬O¹Ð?ªº¨¾ªv) ¡A¦b®ð³Ý±M¬ìÂå®vªº«ü¾É¤U¾A·í¨Ï¥Î¼QÃú§l¤J«¬Ãþ©T¾J(¦³®É©|¶·¥[¤Wªø®Ä«¬¤A¤G«¬¥æ·P¯«¸g¿³¾Ä¾¯¡B¥Õ¤T²m½Õ¸`¯À¡B½wÄÀ«¬¯ùÆP¡B¬Æ¦Ü¤fªAÃþ©T¾J)¡A°t¦X¥²­n®É¤A¤G«¬¥æ·P¯«¸g¿³¾Ä¾¯ªº¨Ï¥Î¡A¬°¥Ø«e®ð³Ý¯fµ£ªº³Ì¨Î³B¸m¤è¦¡¡C·í¤@¦ì¹ï¹Ð?¦³¤¤µ¥µ{«×¥H¤W¹L±Óªº¯fµ£¡A¦b¸g¹L®ð³Ý±M¬ìÂå®vªº¾A·í±Ð¾É©M³B¸m¡A¾¨¶q¦aÁקK»P¹Ð?ªº±µÄ²¡A¨Ã¥B¾A·í¦a¨Ï¥Î§Ü¹L±Ó©Êµoª¢ÃĪ«(¤×¨ä¬O§l¤J©ÊÃþ©T¾J)¨ÓªvÀø¨äªø´Á²Ö¿n¥B¦­¤w¦s¦bªº¹L±Ó©Êª¢¯g¤ÏÀ³¡A«h¤£¦ý¨ä¥Ñ¹Ð?©Ò¤Þ°_ªº¹L±Ó©ÊÁ{§É¯gª¬±o¥HÀò±o½w¸Ñ¡A¥B¯fµ£¹ï¨ä¥¦¦³¶§©Ê¤ÏÀ³¹L±Ó­ìªº±Ó·P«×¥ç¥iÀò±oÅãµÛ¦a­°§C¡C

¡@¡@®a¹Ð?ÄÝ©ó¸`ªÏ°Êª«¡A¨ã¦³¹X¤lª¬ªº¸}¡A«¬ºA¤Î¥Í²z¯S©Ê¬Ò»P©øÂÎÃþ¤£¦P¡C¹Ð?ªº¤ÀÃþ¦a¦ì¬°»jµïºõ¡Bãë?¨Èºõ ( Acarina )¡B?§Î¥Ø(Acariformes)µL®ðªù¨È¥Ø(Astigmata)¡A¹Ð?¬ì (Pyroglyphidae )¡A¤À¥¬©ó¥@¬É¦U¦a¡C¥xÆW¦a°Ï©~®a®a¹Ð¤¤¤§?Ãþ¡A¸g½Õ¬d»PŲ©w«á¡A¦³¤Q¤»ºØ¡A¨ä¤¤¥H«Î¹Ð?¡B¯»¹Ð?¡B·L¨¤¹Ð?¡]Dermatophagoides microceras¡^¡B±ö¤ó¶ÝÅð?¡]Euroglyphus maynei¡^»P¼ö±aµL¤ö?¡]Blomia tropicalis¡^¬°¥xÆW¦a°Ï±`¨£ªº¹Ð?¹L±Ó¨Ó·½¡C®Ú¾Ú¥x¥_°¨°º¬ö©ÀÂå°|µoªíªº¤åÄm³ø§i²Î­p¡A¥xÆW¦a°Ï¹ï¹Ð?¹L±Ó¯fµ£ùØ¡A¹ï©ó¤­ºØ¹Ð?¯S²§©ÊIgE§ÜÅé¥X²{²v¥H«Î¹Ð?³Ì°ª¡]87%¡^¡A¨ä¦¸¬°¯»¹Ð?¡]85%¡^¡A·L¨¤¹Ð?¡]84%¡^¡B±ö¤ó¶ÝÅð?¡]77%¡^»P¼ö±aµL¤ö?¡]65%¡^¡C¨ä¤¤¡A®ð³Ý¯fµ£¦å²M¤¤¹ï©ó«Î¹Ð?¡B¯»¹Ð?¡B·L¨¤¹Ð?»P¼ö±aµL¤ö?ªº¯S²§©ÊIgE§ÜÅé¥H¤¤­««×¬°¦h¡A¦Ó¹ï©ó±ö¤ó¶ÝÅð?«h¥H»´«×¦û¤j¦h¼Æ¡C§Y¨Ï¯fµ£¥¼¥X²{«Î¹Ð?©Î¯»¹Ð?¥ô¦ó¤@ºØ¯S²§©ÊIgE§ÜÅé¡A¤´¦³6.4%¾÷·|¥X²{¨ä¥L¹Ð?ªº¯S²§©ÊIgE§ÜÅé¡C

¡@¡@®a¹Ð?ªº¥Í©R¶g´Á¦³¤­­Ó¶¥¬q¡G§Z¡B¥®ÂΡB²Ä¤@­Y?¡]protonymph¡^¡B²Ä¤T­Y?¡]tritonymph¡^¤Î¦¨ÂΡA¦¨ÂΤ§«á¶i¦æ¦³©Ê¥Í´Þ¡C±q§Z¨ì¦¨ÂΪº¾ã­Óµo®i¹Lµ{¡A¨ü¨ì¥~¬É·Ã«×¤Î·Å«×ªº¼vÅT«Ü¤j¡C¨Ò¦p«Î¹Ð?³Ì¾A©y¦¨ªøªº·Å«×¬OÄá¤ó¤G¤Q¤­«×¡A¤Ó°ª©Î¤Ó§Cªº·Å«×¬Ò·|¨Ï¹Ð?ªº¥Íªø½wºC¡C¦¹¥~®a¤¤¤£¦P¦a¤èªº¹Ð?¡A¦]·Å«×ªº¤£¦P¡A¦¨ªøªº³t«×¤]¤£¦P¡C¨Ò¦p¦b¦B§N¦aªO¤Wªº¦a´à¤¤ªº¹Ð?¡A¨ä¥Íªø³t«×«h¤ñ¨Fµo¤¤ªº¹Ð?ÁÙºC¡C

¡@¡@°£¤F·Å«×¤§¥~¡A·Ã«×¹ï©ó¹Ð?ªº¼vÅT¥ç¬Û·í¤j¡C¹Ð?Å餺ªº¤ô¤À§t¶q¬ù¦ûÅé­«ªº¦Ê¤À¤§¤C¤Q¦Ü¤C¤Q¤­¡A¥¦­ÌÂǥѧl¦¬¥~¬ÉªÅ®ð¤¤ªº¤ô»]®ð¨Ó¹F¨ìÅ餺¤ô¤Àªº¥­¿Å¡C¹Ð?©Ò»ÝªºÀô¹Ò·Ã«×¡AÀH©P¾Dªº·Å«×¤£¦P¦Ó²§¡C¨Ò¦p¯»¹Ð?¦bÄá¤ó¤G¤Q¦Ü¤G¤Q¤­«×ªº±¡§Î¤U¡A¨¬¥Hºû«ùÅ餺¤ô¤Àªº¥­¿Åªº³Ì§C©³­­Àô¹Ò·Ã«×¬O¦Ê¤À¤§¤­¤Q¤­¡C

¡@¡@¹Ð?ªºÁT«K¡B³è²G¡B«ÍÅé¤Î¥Í´Þ¹Dªº¤Àªcª«¬Ò·|³y¦¨¹L±Ó¤ÏÀ³¡C¥Ø«e¹Ð?­P±Óª«½è®Ú¾Ú¤£¦Pªºµ²ºc¦¨¥÷¡B§Ç¦C¤Î¤À¤l¶q¡A¤À¦¨¤F¤Q´XºØ¡C¹Ð?§t¦³ªº¹L±Ó­ì¦³¡G(1)¥b¯ÖÓi»Ä¤ô¸Ñ?(cysteine proteases)²Ä¤@¸s¹L±Ó­ì¡G(D. pteronyssinus¢¹¡AD. farinae¢¹©MD. microceras¢¹)¡A(2)µ·Ói»Ä¤ô¸Ñ?(serine proteases) (²Ä¤T¸s¹L±Ó­ì)¡A(3)¾ý¯»?(amylase) (²Ä¥|¸s¹L±Ó­ì)¡C³o¨Ç¨ã¹L±Ó­ì¯S©Êªº»Ã¯À¦s¦b©ó¹Ð?ªº±Æªnª«¤¤¡C¨ä¤¤Der p 1¬O³Ì¥D­nªº­P±Óª«½è¡A¥¦¬OÄÝ©ó¥b¯ÖÓi»Ä³J¥Õ?¡A·½¦Û©ó¹Ð?®ø¤Æ¹Dªº¤W¥Ö²Ó­M¡A¥D­n¬O¥Î¨Ó®ø¤Æ­¹ª«¡C²Ä¤G¸s¹L±Ó­ì«h¥D­n¨Ó¦Û¹Ð?ªºÂßÅé¦Ó«D±Æªnª«(D. pteronyssinus II¡AD. farinae II)¡C®a¹Ð¤¤¥D­nªº¹L±Ó­ì¬°²Ä¤@¸s©M²Ä¤T¸s¡C

¹Ð?¾É­P¹L±Ó¤ÏÀ³¥i¯à¤§¾÷Âà¦p¤U¡G

1. »¤µo²Ä¤G«¬T²Ó­M´C¤¶§K¬Ì¤ÏÀ³¡]Th2-mediated immune response¡^¡G

Der p 1·|¥[±j¶Ý¥ì¬õ©Ê¥Õ¦å²y¡]eosinophil¡^©MªÎ­D²Ó­M¡]mast cell¡^ªº§@¥Î¡A¦ÓÄÀ©ñ¥X¤j¶qªº«eµoª¢¤¶½è¡]pro-inflammatory mediator¡^¡A¦Ó¾É­P¤Fµoª¢¤ÏÀ³¡C
Der p 1¥ç·|¼vÅTT²Ó­M°¾¦V¡A¨Ï¨ä¤Àªc¸û¦h²Ä¤G«¬T²Ó­M´C¤¶§K¬Ì¤ÏÀ³ªº²Ó­M¿E¯À¡]type 2 cytokine¡^¡C

2. ¯}ÃaCD23¡G
CD23¬OB²Ó­M¤Wªº§K¬Ì²y³J¥ÕE¡]IgE¡^±µ¨üÅé¡A·í§K¬Ì²y³J¥ÕEµ²¦X¨ìCD23®É¡A·|²£¥Í­t¦^õX¦Ó§í¨î§K¬Ì²y³J¥ÕEªº¦X¦¨¡C¦ý­YCD23¾D¨ì¥b¯ÖÓi»Ä³J¥Õ?µõ¸Ñ¡]cleavage¡^¡A«h§K¬Ì²y³J¥ÕEªº¦X¦¨±NµLªk¨ü¨ì§í¨î¡C

3. µõ¸ÑT²O¤Ú²y¤W¤¶¥Õ½è-2±µ¨üÅé¡]IL-2 receptor¡FCD25¡^¡G
Der p 1µõ¸Ñ¤FT²O¤Ú²y¤W¤¶¥Õ½è-2±µ¨üÅé¡A¦]¦Ó´î¤Ö¤FT²O¤Ú²yªº¼W¥Í¤Î¤þ«¬¤zÂZ¯À¡]interferon-£^¡^ªº²£¥Í¡A¦Ó°¾¦V¤F²Ä¤G«¬T²Ó­M´C¤¶§K¬Ì¤ÏÀ³¡C

4. ¯}Ãa©I§l¹D¤W¥Ö¡G
¥b¯ÖÓi»Ä³J¥Õ?·|ª½±µ¯}Ãa©I§l¹D¤W¥Ö¡A³y¦¨³q³z©Ê¼W¥[¡A¨Ï¹L±Ó­ì§ó®e©ö³q¹L¤W¥Ö²Õ´¡C

5. §í¨î£\1-antitrypsin¡G
£\1-antitrypsin¬O¦b©I§l¹D¤¤¥D­nªº§Ü³J¥Õ?¡]antiprotease¡^¡A¥¦·|§í¨î©I§l¹D¤¤³J¥Õ?ªº§@¥Î¡]¨Ò¦p²Óµß³J¥Õ?¡^¡A¨¾¤î²Ó­M³Q¯}Ãa¡CµM¦ÓDer p 1·|§í¨î£\1-antitrypsinªº¬¡©Ê¡A¾É­P©I§l¹D¤W¥Ö²Õ´ªº¶Ë®`¡C

®a¤¤¹Ð?¨¾ªvªº°¨°º¸gÅç¤À­z¦p¤U¡G

1. ­°§C«Ç¤º·Ã«×¡G
«O«ù«Ç¤º·Ã«×¦b¦Ê¤À¤§¤­¤Q¥H¤U¡A¬O­°§C¹Ð?¤Î¨ä­P±Óª«³Ì­«­nªº¤èªk¡C¥i¨Ï¥Î°ª®Ä¯à°£Àã¾÷©Î§N®ð¾÷¨Ó­°§C«Ç¤º·Ã«×¡C

2. ²¾°£¦a´à¡B«pµ¡Ã®¥¬¡B§¤¹Ô¤Î¼u®§É¡G
¦]¦a´à¡B«pµ¡Ã®¥¬¡B§¤¹Ô¤Î¼u®§É®e©ö»W¿n¥Ö®h©M«O¯d¤ô¤À¡A¬O¹Ð?¥Íªøªº·Å§É¡C©Ò¥H«Øij§â¦a´à¤Î¼u®§É²¾°£¡A«pµ¡Ã®¥¬§ï¦¨¸ûÁ¡ªº§÷½è©Î¦Ê¸­µ¡¡A¨Fµo©Î´È¹Ôªºªí­±¥Î¥Ö­²§÷½è©Î¥H¤ì»s®a¨ã¨ú¥N¡C¹ï¹Ð?¨ã¦³ÄY­«¹L±Óªº¯fµ£®a®x¡A³Ì¦n¶·¥þ®aºÎ¤ìªO§É©Î¦aªO¤W¹Ô¥HÃý«ß¾Þ¥Îªº¶ì½¦«÷¹Ô¡F¥þ®a©Ò¦³ªº©Ð¶¡¶·²¾°£¼u®§É¹Ô¡B·¦µ·¹Ô¡B¤Î®üºø¹Ô¡A¤£¥i¨Ï¥Î¯ó»V¡Bºfºf¦Ì¡B¯D¤y³Q¡B¤ò´à¡B©Î«p­«ªººø³Q¡A§_«h¶·¥H¸g¬ü°ê­¹«~ÃĪ«ºÞ²z§½»{ÃÒªº¨¾?®M®M¤§¡C

3. µLªk²¾°£¼u®§É®É¡A¶·¨Ï¥Î¸g¬ü°ê­¹«~ÃĪ«ºÞ²z§½»{ÃÒªº¨¾?®M®M¤§¡G
®Ú¾Ú§Ú­Ìªº¬ã¨s²Î­p¡A²¾°£¼u®§É¤»¶g«á¡A¥­§¡¹Ð?¿@«×¤U­°61%(Der p 1, ELISA)¡A¦y®p¦R®ð¬y³t¡]PEFR¡^¥­§¡¤W¤É49¤É/¤À¡]l/min¡^¡A®ð³ÝÁ{§É¯gª¬¤À¼Æ¥­§¡¶i¨B4.2¤À¡C¦Ó¨Ï¥Î¬ü°ê­¹«~ÃĪ«ºÞ²z§½»{ÃÒªº¨¾?®MªÌ¡A«h¥­§¡¹Ð?¿@«×¤U­°62.4%¡A¦y®p¦R®ð¬y³t¥­§¡¤W¤É68¤É/¤À¡A®ð³ÝÁ{§É¯gª¬¤À¼Æ¥­§¡¶i¨B3.15¤À¡C¨âºØ±¡ªp»P¥¼²¾°£¼u®§É¤]¥¼¨Ï¥Î¨¾?®MªÌ¤ñ¸û¡A²Î­p¤W¬Ò§e²{¦³·N¸qªº§ïµ½¡C

4. ¹ì¨ãªº¬~º°¡G

¦Ü¤Ö¤@­Ó¬P´Á¥ÎÄá¤ó¤­¤Q¤­«×¥H¤Wªº¼ö¤ô©Î¯M°®¾÷¥ý³B²z¹ì¨ã¡]ªEÀY®M¡B³Q¤l¡B§É³æ¡^¤Q¤ÀÄÁ¡A¦A¥H²M¤ô¬~º°°®²b¡A¨â­Ó¨BÆJ¯Ê¤@¤£¥i¡C¦]¬°¯M°®©Î°®¬~¥u¯à±þ¦º¹Ð?¡A«oµLªk¯}Ãa©Ò¦³ªº­P±Óª«½è¡C¦Ó­Y³æ³æ¥u¦³¤ô¬~¡A«h¥i¥h°£­P±Óª«½è¡]¦]¨ä¬°¤ô·»©Ê¡^¡A¦ý«oµLªk¨Ï¹Ð?¦º¤`¡C©Ò¥H¨Ï¥Îªº¹ì¨ã§÷½è¥²¶·¥i­@¼ö¤ô²M¬~ªº¡C

5. ¥H¦³°ª®Ä¯à²É¤lªÅ®ð¹LÂo¡]high-efficiency particulate air filter¡FHEPA¡^¨t²Îªº §l¹Ð¾¹§l¦a´à¡G
­Y¤£Ä@·N©ÎµLªk²¾°£¦a´àªº¸Ü¡A«h¦Ü¤Ö¤@¬P´Á¥HHEPA§l¹Ð¾¹§l¦a´à¤@¦¸¡A¥B­n¶Ô©ó§ó´«§l¹Ð¾¹³U¤l¡C§l¹Ð¾¹³U¤l­n¦³¨â¼h¡A¥H¨¾¤î­P±Óª«¦b§l¹Ðªº¹Lµ{¤¤¨T¤Æ¡C¤£¹L§Y¨Ï¦p¦¹¡A§l¹Ð¾¹ÁÙ¬O¥u¯à²¾°£ªí­±ªº¹Ð?¤Î¨ä­P±Óª«¡A¸û²`¼hªº«h¨S¦³¿ìªk¡C

6. ¦B­á¹Ð?¡G
¨C­Ó§«ô§â¶ñ¥Rª±¨ã¡B¤pª±°¸¡B¤pªEÀY©Î¦çªA©ñ¤J§N­á®w¤¤¡Aºû«ùÄá¤ó¹s¤U¤Q¤C¦Ü¹s¤U¤G¤Q«×¤G¤Q¥|¤p®É¥H¤W¡A¥i¥H¦³®Äªº±þ¦º¹Ð?¡C¤§«áÁٻݥH²M¤ô¬~º°¡A¥H¥h°£¹Ð?«ÍÅé¤Î­P±Óª«¡C

7. ªÅ®ðÂo²b¡G
¦í®aªÅ®ðÂo²b¾¹¡]¥]¬AHEPA¡^¬O±`¥Îªº¾÷±ñ¹LÂo¾¹¡A¨ä¦b©~®a¹Ð?¨¾ªvªº¨¤¦â©|¥¼½T©w¡C

8. ²M²zªÅ½Õ¨t²Î¤ÎÂoºô¡G
¦]¹Ð?«Ü¤Ö»E¿n¦bªÅ½Õ¨t²Î¤¤¡A©Ò¥H¦¹¨BÆJ¬O¤£»Ý­nªº¡C¦ý¦¹¨BÆJ¥i¥h°£¦Ç¹Ð¡B¸H®h¤ÎÅðµß¹L±Ó­ì¡C

9. ¯ä®ñ»s³y¾÷¡G¥Ø«e¨S¦³ÃÒ©ú¬O¦³®Äªº¡C

10. ¨Ï¥Î±þ?¤Æ¾Ç»s¾¯¡G

¦³¨Ç¤Æ¾Ç¾¯¡A¦p benzyl benzoate pyrethroids¡BPhenyl salicylate¥i¥H±þ¦º¹Ð?¡F
Natamycin¥i¥HÂǥѱþ¦ºÅðµßÌU¤l(¹Ð?ªº­¹ª«)¦Ó´î¤Ö¹Ð?ªº¶q¡FTannic acid¥i¥H§ïÅܹÐ?¹L±Ó­ìªºµ²ºc¦Ó­°§C¨ä­P±Ó©Ê¡C¼vÅT±þ?¾¯¥\®Äªº­ì¦]¥]¬A¨Ï¥Î¤èªk¡B¾¯«¬¡B¬I¥ÎªºÀô¹Ò¥H¤Î¨Ï¥Î³o¨ÇÃľ¯«á²¾°£³o¨Ç§Ü­ìªº¦³®Ä©Ê¡C¨ì¥Ø«e¬°¤îªº¬ã¨s¨Ã¨S¦³±o¨ì¤@­Pªºµ²½×¡A¦]¦¹¤£«Øij¨Ï¥Î±þ?¾¯¡C¦³¬ã¨s«ü¥X±N0.03%­f¥Ò°ò­f¥Ò»ÄÆQ¡]benzyl benzoate¡^©M0.2%ÑÛ¾ð´Óª«ªo¡]eucalyptus oils¡^­Ë¤J¬~¦ç¾÷¤¤¤]¥i±þ¦º¹Ð?¡A¦ýÑÛ¾ð´Óª«ªoªº¨ý¹D·|¦b¦çªA¤W´Ý¯d2¦Ü3¤Ñ¡C

11. ¦b§@©~®aÀô¹Ò²M¼ä®É¡A¹Ð?¹L±Óªº¯f¤HÀ³¦b²M¼ä®É¤Î²M¼ä«á1¤p®É¤º»·Â÷¸Ó³B¡C

12. ¹ï©ó¹Ð?¦Ó¨¥¡Aª¯¿ßªº¥Ö®h¥i¥H¬O¨ä­¹ª«¡A©Ò¥H²¾°£Ãdª«¹L±Ó­ì¹ï©ó¹Ð?¹L±Óªº¤H¤]¦³À°§U¡C

µ²½×
¥xÆW¦a³B¨È¼ö±a¡A²×¦~·Ã«×°ª¡A¥|©u¤£©úÅã¡A¥B¥Í¬¡Àô¹Ò¾ÖÀ½¡A¦]¦¹®a¤¤ªº
¹Ð?¬O¹L±Ó®ð³Ý¯fµ£³Ì­«­nªº¹L±Ó­ì¡C©Ò¥H¦p¦ó°µ¦n¹Ð?ªº¨¾ªv¤u§@¬O¥xÆW¦a°Ï¨C­Ó¦³¹L±Ó¿ò¶ÇÅé½è®a®x³Ì­¢¤Á»Ý­nªº¤u§@¡C

 
 
 
 
 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 
 
 

 

 

¡@
®}¥@¹FÂå®vª©Åv©Ò¦³¡BÂà¸ü¥²¨s
¨àµ£¹L±Ó®ð³Ý¡B§K¬Ì­·Àã°ÝÃD¿Ô¸ß¡G ®}¥@¹F¥D¥ô abc1016@ms2.mmh.org.tw
¿Ô¸ß±M½u¡G0935-545-141, 02-2511-8589 ¡£¿Ô¸ß®É¶¡¡G9:00AM ~ 12:00PM¡¤
¡@